Home / Going-concern warnings / Outlook Therapeutics, Inc.
Filed 2025-08-14 路 Form 10-Q 路 Accession 0001558370-25-011588 micro
Price before filing: $2.13 (2025-08-13 close, split/dividend-adjusted)
Market cap at flag: $84.6M (2025-08-14) 路 Latest: $12.4M (2026-10-16)
| Window | OTLK | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -50.7% | +2.5% | -53.2% | 2025-09-15 |
| 90 days | -39.9% | +6.3% | -46.2% | 2025-11-12 |
| 180 days | -80.2% | +7.9% | -88.2% | 2026-02-10 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"As a result, there is substantial doubt about the Company's ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-06-30)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.